PROMIS – PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score

Publication Name: Cancer Research

Author(s): Hatem Soliman, Sarah Untch, Lisette Stork-Sloots

PROMIS is a prospective study that will investigate the additional value of MammaPrint, BluePrint and TargetPrint in women with an intermediate Oncotype DX score. An initial CRF – capturing baseline patient characteristics, pathology information, Oncotype DX score and the recommended … Continued

MINT I – Multi-Institutional Neoadjuvant Therapy, MammaPrint Project I

Publication Name: Cancer Research

Author(s): Charles Cox, Peter Blumencranz, Douglas Reintgen, Ruben Saez, Nicole Howard, Jessica Gibson, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück

Treatment of locally advanced breast cancer (LABC) with neoadjuvant chemotherapy measures the in vivo response to chemotherapy,1 assesses long-term clinical outcomes associated with that response2,3 and enables some patients to undergo breast-conservation therapy due to therapeutic down-staging of the tumor.  In the current study, the … Continued

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer

Publication Name: Cancer Research

Author(s): C.A. Drukker, M.V. Nijenhuis, S.G.Elias, J. Wesseling, N.S. Russell, P. Whitworth, R. Patel, F. de Snoo, L.J. van’t Veer, P.D. Beitsch, E.J.Th. Rutgers

The 70-­‐gene signature is able to predict the risk of locoregional recurrence. We observed a significantly lower incidence of locoregional recurrence in patients with a low risk 70-­‐gene signature result compared to those with high risk 70-­‐gene signature result, independent … Continued

Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial

Publication Name: SABCS 2012 Poster

Author(s): Giuseppe Viale, Leen Slaets, Femke de Snoo, Laura J. van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Jan Bogaerts, Jeroen van den Akker, Lisette Stork-Sloots, Kristel Engelen, Leila Russo, Patrizia Dell’Orto, Fatima Cardoso

Biology has become the main driver of breast cancer therapy. Intrinsic biological subtypes by gene expression profiling have been identified.  Pathology can be used to define surrogates of these subtypes but these are not always concordant, which may lead to … Continued

Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer

Publication Name: 2012 ASCO Gastrointestinal Cancers Symposium, JCO Abstract

Author(s): Josep Tabernero, Victor Moreno, Robert Rosenberg, Ulrich Nitsche, Thomas Bachleitner-Hofmann, Giovanni Lanza, Jeroen van den Akker, Paul Roepman, Iris Simon, Ramon Salazar; Vall d'Hebron University Hospital, Barcelona, Spain; IDIBELL, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Medizinische Universitaet Wien, Vienna, Austria; Department of Experimental and Diagnostic Medicine, Section of Anatomic Pathology, Ferrara, Italy; Agendia BV, Amsterdam, Netherlands; Institut Catala d'Oncologia, Barcelona, Spain

Background: Between 25 and 35% of stage II colon cancer patients will experience a relapse of their disease and may benefit from adjuvant chemotherapy. ColoPrint is a gene expression classifier that can predict disease relapse in patients with early-stage colorectal … Continued

Response to neo-adjuvant chemotherapy and outcomes for I-SPY 1 patients stratified by the 70-gene prognosis signature (MammaPrint) and molecular subtyping (BluePrint)

Publication Name: Cancer Research, Poster

Author(s): Stefan Glück, Femke de Snoo, Sun Tian, Annuska Glas, Laura van 't Veer

Classification of breast cancers into molecular subtypes may be important for the proper selection of therapy for patients as tumors with seemingly similar biology can have strikingly different clinical outcomes. The multi-center neo-adjuvant I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) … Continued

A gene profile that identifies molecular subtypes of breast cancer is highly enriched in genes having Estrogen Receptor binding sites

Publication Name: ASCO 2011 Poster

Author(s): W. Zwart, F. De Snoo, et al

Classification of breast cancer into molecular subtypes may be important for the proper selection of therapy, as tumors with seemingly similar biology can have strikingly different clinical outcomes. We have previously developed an 80-gene molecular subtyping profile (BluePrint) for the classification of breast cancer into three … Continued

The PARSC Trial, a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Publication Name: ASCO 2011 Poster

Author(s): R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall4 , J. J. M. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots

Background: An 18-gene expression profile, ColoPrint, has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy. The gene signature was validated in in-silico datasets and independent patient cohorts of stage … Continued

Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients

Publication Name: ASCO GI 2011

Author(s): R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, I. Simon, R. Bender, K. P. Janssen and H. Friess

Background: Adjuvant therapy is not routinely recommended for stage II CC patients but may be considered for high-risk patients. In this study we aim to independently validate a genomic profile that was developed to identify high-risk patients and can assist in … Continued

Gene Signatures as predictors of response to neoadjuvant chemotherapy with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel and carboplatin +/- trastuzumab in patients with stage II-III and inflammatory breast cancer.

Publication Name: ASCO Poster 2010

Author(s): G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L. Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender

Pathologic complete response (pCR) and residual cancer burden (RCB) scores of 0 (pCR) and 1 (near CR) after NCT predict for better survival (Symmans et al. J Clin Oncol 25:4414-22, 2007). Improved NCTs and molecular markers predicting for response are … Continued